



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada, 5 November 2015

RELEVANT FACT NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge the following information about Neuron Bio, S.A. (hereinafter "NEURON" or "Company").

On 28 October 2015 Neuron Bio has created the company Neuron Bio USA INC in the state of Massachusetts.

The creation of this company has the aim to accelerate all the developments related to the diagnostic area of NEURON'S strategic plan and to open up the market in the American continent.

Press release is enclosed.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Press release

Neuron Bio joins the USA market

Granada, 06 November 2015. Neuron Bio (ticker: NEU), a leading company in biotechnology solutions created the company Neuron Bio USA INC in Boston, Massachusetts the last 28 October.

With the creation of a new corporation it is aimed to develop its strategic plan in the field of diagnostic for Alzheimer's disease and to establish the contacts for the commercialization of the technologies developed in this area.

According to Javier S. Burgos, CEO of Neuron Bio, "Valorization of our developments in the field of diagnostic for Alzheimer's involves joining the great American market. Due to this we have decided to constitute this new company in the USA with the main goal to strengthen this business line and to look for strategic partners that allow us to place in the market our developments in a minimum time possible. This was a step already outlined in our business plan. After recent positive contacts and negotiations we have opted for the area of Boston, the most appropriate for Neuron Bio due to its considerable concentration of biotech and pharma companies."

The Boston area houses one of the world's largest biotechnology cluster that currently has over 400 biotech companies, aside from the big pharmaceutical companies, specialized investors, patent lawyers, CROs (Contract Research Organization), etc.

Massachusetts is characterized by the presence of large research centers, centers of excellence and reference hospitals that are particularly interesting for the activity in the field of diagnostics for neurodegenerative diseases to be carried out by Neuron Bio Inc. Universities of Harvard and Boston, the MIT, the Massachusetts General Hospital and the Boston Medical Center are included among others.

U.S. cluster rankings

Rank	Cluster	Weighted score
1	Greater Boston Area	72.5
2	Raleigh-Durham	66.4
3	San Francisco Bay Area	64.3
4	San Diego	63.1

	2014	2015	Change Y-o-Y
Boston	\$11.10 p.s.f.	\$17.40 p.s.f.	7.4%
Raleigh-Durham	\$16.90 p.s.f.	\$19.00 p.s.f.	12.4%
San Francisco	\$31.90 p.s.f.	\$37.30 p.s.f.	16.9%
San Diego	\$25.80 p.s.f.	\$29.90 p.s.f.	15.5%

Life sciences employment concentration: Weight: 25.0% Measured as the percent of industry employment against total metro private employment.
Life sciences employment growth: Weight: 10.0%
Life sciences establishments concentration: Weight: 10.0% Measured as the percent of industry establishments against total metro private establishments.
Life sciences venture capital funding: Weight: 20.0%
Life sciences National Institute of Health funding: Weight: 20.0 %
Life sciences patents: Weight: 15.0%

Figure 1: Ranking of the main biotechnological clusters of USA (source: Big3Bio Boston).

Venture Capital Investment

Investment in Massachusetts Biotech Companies, 2005-2014




Figure 2: Investment in Massachusetts biotech companies (source: EvaluatePharma).



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

For more information

Malena Valdivieso
mvaldivieso@neuronbio.com
Tel.: +34 958 750 598



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Note for editors:

About Neuron Bio

Neuron Bio (NEU.MC) develops and manages biosolutions and projects in the biotechnological field for their application in the pharmaceutical and oleochemical industry through its subsidiaries and its specialized areas.

Its **pharma division** is mainly devoted to the search of drugs for the prevention and treatment of neurodegenerative diseases, particularly for the Alzheimer's disease.

Its **diagnostic division** develops tools and biomarkers for the diagnosis of human diseases, principally for those of the Central Nervous System as the Alzheimer's disease.

Its **service division** develops research projects as well as consultancy services for public institutions and for companies of the pharmaceutical, biotechnological, agro-food and animal health area.

Neuron Bio owns a broad and diverse high value molecule collection, neuroprotective compounds, 10 patent applications (2 of them recently granted by the European Union and other one (1) also granted by the US Patent and Trademark Office) and exclusive platforms for drug discovery and development.

Neol Bio (NEOL.MC), a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

It has a highly qualified team of researchers with wide experience in R&D and renowned prestige in the sector, who participate actively in numerous scientific projects.

Neuron Bio has facilities in Granada and Madrid connected with university research centers and is listed at the Alternative Stock Market (MAB) in Spain.